AstraZeneca is beginning to look a lot like Tesco
It might be tempting to view last week’s fall in the AstraZeneca share price in isolation, related to the disappointing results of the “Mystic” lung cancer drug trial. However, I suspect that AstraZeneca’s problems go much deeper than a setback for a single drug.